{"ticker": {"uuid": "f6db1008-c56f-44d2-9216-b4268cb66ffa", "symbol": "MRK", "name": "Merck & Company Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "5 Insightful Analyst Questions From Merck\u2019s Q2 Earnings Call", "summary": "5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, \"Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline.\" While market reaction was muted, management acknowledg", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-merck-234100386.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T23:41:00+00:00", "published_display": "12 Aug 2026 23:41", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.5, "duplicate_count": 1, "topics": ["Clinical Trials", "Earnings", "Guidance", "Oncology", "Pharma"]}, {"title": "Sector Update: Healthcare Stocks Advance Late Afternoon", "summary": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T19:58:41+00:00", "published_display": "12 Aug 2026 19:58", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.389, "duplicate_count": 1, "topics": []}, {"title": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?", "summary": "Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio \u2014 including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy \u2014 is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving r", "url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T18:36:00+00:00", "published_display": "12 Aug 2026 18:36", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.482, "duplicate_count": 1, "topics": ["Immuno Oncology", "Oncology", "Pharma", "Revenue Growth"]}, {"title": "U.K. regulator reaffirms safety of childhood vaccination", "summary": "[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin", "url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-12T13:13:40+00:00", "published_display": "12 Aug 2026 13:13", "sentiment": "neutral", "sentiment_pct": 54, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.184, "duplicate_count": 1, "topics": ["Healthcare", "Regulation", "Split", "Vaccines"]}, {"title": "Why Revolution Medicines May Be Big Pharma\u2019s Next Takeover Target", "summary": "Quick Read RVMD has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. MRK ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure and CEO Robert Davis pledging to diversify its growth portfolio. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Revolution Medicines (NASDAQ:RVMD) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform ", "url": "https://finance.yahoo.com/healthcare/articles/why-revolution-medicines-may-big-125024116.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:50:24+00:00", "published_display": "12 Aug 2026 12:50", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.37, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Fda Approval", "M A", "Oncology", "Price Target"]}, {"title": "Here Are Wednesday\u2019s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More", "summary": "Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price index will be released at the same time tomorrow. Economists forecast headline CPI to rise 0.1% month-over-month and 3.4% year-over-year, with core CPI expected to increase 0.2% month-over-month and 2.5% year-over-year. One thing is for sure; if the numbers come in hot and above expectations, the stock market could see a bout of heavy selling. All of the major ind", "url": "https://finance.yahoo.com/markets/stocks/articles/wednesday-top-wall-street-analyst-115341914.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:53:41+00:00", "published_display": "12 Aug 2026 11:53", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.367, "duplicate_count": 1, "topics": ["Crypto", "Earnings", "Price Target", "Price Target", "Upgrade Downgrade"]}, {"title": "Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children", "summary": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. The filings seek to broaden ENFLONSIA's indication in vulnerable pediatric groups where preventative options for RSV are limited. The dual U.S. and European regulatory milestones highlight Merck's efforts to build out its portfolio beyond oncology as attention on the future of Keytruda intensifies. For i", "url": "https://finance.yahoo.com/healthcare/articles/merck-mrk-wins-fda-ema-181430790.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T18:14:30+00:00", "published_display": "11 Aug 2026 18:14", "sentiment": "neutral", "sentiment_pct": 55, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.284, "duplicate_count": 1, "topics": ["Fda Approval", "Healthcare", "Pharma", "Vaccines"]}, {"title": "MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?", "summary": "Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as higher sales of oncology drugs, including Keytruda, and contributions from new products like Winrevair, Welireg, and Capvaxive, and the Animal Health segment were partially offset by lower sales of Gardasil and some other vaccines. Sales of blockbuster PD-L1 inhibitor Keytruda increased 4% to $8.4 billion. Merck also raised its 2026 revenue", "url": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:48:00+00:00", "published_display": "11 Aug 2026 13:48", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.391, "duplicate_count": 1, "topics": ["Acquisitions", "Earnings", "Oncology", "Patent Expiration", "Pharmaceuticals", "Revenue Growth"]}, {"title": "The Galien Foundation Announces 2026 Prix Galien USA Nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\"", "summary": "A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo \"We are proud to recog", "url": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:00:00+00:00", "published_display": "11 Aug 2026 13:00", "sentiment": "positive", "sentiment_pct": 69, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.447, "duplicate_count": 1, "topics": ["Biotech", "Fda Approval", "Pharmaceuticals", "Rare Diseases"]}, {"title": "ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer", "summary": "Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business Officer Appointments deepen vaccine development expertise and enhance global commercial and strategic leadership WESTON, Fla., August 11, 2026--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisit", "url": "https://finance.yahoo.com/healthcare/articles/iliad-biotechnologies-expands-board-directors-123000980.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:30:00+00:00", "published_display": "11 Aug 2026 12:30", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.252, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Vaccine Development"]}, {"title": "S&P 500 Companies' Quarterly Earnings Growth Eases Amid Healthcare Drop, Oppenheimer Says", "summary": "S&P 500 companies' quarterly earnings growth rate eased from a week ago amid a drop in the healthcar PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/markets/stocks/articles/p-500-companies-apos-quarterly-180206082.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T18:02:06+00:00", "published_display": "10 Aug 2026 18:02", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.339, "duplicate_count": 1, "topics": ["Growth Rate", "Quarterly Earnings"]}, {"title": "Glioma Market is Set for Tremendous Growth at a CAGR of 15% During the Study Period (2022\u20132036), as Novel Targeted Therapies and Immunotherapies are Gaining Momentum | DelveInsight", "summary": "DelveInsight Business Research LLP The glioma market is expected to witness steady growth over the coming years, driven by the rising incidence of primary brain tumors, increasing awareness, and advances in diagnostic technologies. The market is also benefiting from a robust pipeline of therapies, including Regorafenib (Bayer), AV-GBM-1 (Aivita Biomedical), Enzastaurin (DB-102) (Denovo Biopharma), Paxalisib (GDC-0084) (Kazia Therapeutics), and others, aimed at improving patient outcomes. New York, USA, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Glioma Market is Set for Tremendous Growth at a CAGR of 15", "url": "https://finance.yahoo.com/healthcare/articles/glioma-market-set-tremendous-growth-170000207.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T17:00:00+00:00", "published_display": "10 Aug 2026 17:00", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.387, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Glioma", "Market Research Reports", "Pharma"]}, {"title": "IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum", "summary": "Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while valuation and weak Zacks Style Scores temper the case for simply extrapolating the recent move. IMCR's 3-Month Rally Puts Growth in Focus IMCR shares have climbed more than 20% over the past 12 weeks. That compares with gains of 6.4% over four weeks and 0.6% over one week, making the longer recent advan", "url": "https://finance.yahoo.com/markets/stocks/articles/imcr-jumps-21-2-3-161600739.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T16:16:00+00:00", "published_display": "10 Aug 2026 16:16", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.335, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Price Target"]}, {"title": "IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss", "summary": "Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consensus estimate of a loss of 1 cent. Kimmtrak remained the central growth driver, while a temporary U.S. distributor stocking benefit complicates the third-quarter setup. Higher research spending and a sizable cash balance also frame the company's push to broaden its melanoma opportunity. IMCR's Q2 Sales Beat Shows Kimmtrak Strength Kimmtrak generated $74.9 mill", "url": "https://finance.yahoo.com/healthcare/articles/imcr-q2-revenues-climb-18-153900256.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:39:00+00:00", "published_display": "10 Aug 2026 15:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.333, "duplicate_count": 1, "topics": ["Consensus Estimate", "Earnings", "Melanoma", "Pharma", "Ratings"]}, {"title": "BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?", "summary": "Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. BMY Outperforms Industry, Sector & S&P 500 IndexZacks Investment Research Image Source: Zacks Investment Research The company reported better-than-expected second-quarter results on July 30, supported by robust demand for Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag. Results were also boosted by strong Eliquis performan", "url": "https://finance.yahoo.com/healthcare/articles/bmy-rallies-16-2-three-151500081.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:15:00+00:00", "published_display": "10 Aug 2026 15:15", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.332, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Generic Competition", "Guidance", "Immuno Oncology"]}, {"title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "summary": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-09T13:05:04+00:00", "published_display": "09 Aug 2026 13:05", "sentiment": "negative", "sentiment_pct": 43, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.275, "duplicate_count": 1, "topics": ["Consensus Estimate", "Earnings", "Earnings Per Share", "Guidance", "Healthcare", "M A"]}, {"title": "Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week", "summary": "Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] (XLV [https://seekingalpha.com/symbol/XLV]) rose 1.36% in the week so far. On a YTD basis, XLV has added more than 5%; however, it is lagging behind the broader S&P ", "url": "https://seekingalpha.com/news/4629325-earnings-scorecard-95-healthcare-firm-deliver-eps-wins-this-week?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-08T15:15:33+00:00", "published_display": "08 Aug 2026 15:15", "sentiment": "positive", "sentiment_pct": 57, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.235, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Earnings News", "Guidance", "Healthcare", "Pharma"]}], "by_tier": {"direct": [{"title": "5 Insightful Analyst Questions From Merck\u2019s Q2 Earnings Call", "summary": "5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, \"Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline.\" While market reaction was muted, management acknowledg", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-merck-234100386.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T23:41:00+00:00", "published_display": "12 Aug 2026 23:41", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.5, "duplicate_count": 1, "topics": ["Clinical Trials", "Earnings", "Guidance", "Oncology", "Pharma"]}, {"title": "Sector Update: Healthcare Stocks Advance Late Afternoon", "summary": "Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-195841095.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T19:58:41+00:00", "published_display": "12 Aug 2026 19:58", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.389, "duplicate_count": 1, "topics": []}, {"title": "Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?", "summary": "Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio \u2014 including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy \u2014 is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving r", "url": "https://finance.yahoo.com/healthcare/articles/bmys-growth-portfolio-strong-enough-183600346.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T18:36:00+00:00", "published_display": "12 Aug 2026 18:36", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.482, "duplicate_count": 1, "topics": ["Immuno Oncology", "Oncology", "Pharma", "Revenue Growth"]}, {"title": "U.K. regulator reaffirms safety of childhood vaccination", "summary": "[Syringe drawing liquid medication from medical vial] zhikun sun/iStock via Getty Images Days after President Donald Trump ordered major changes to the U.S. childhood immunization schedule, the U.K. drug regulator on Wednesday reaffirmed the safety of pediatric vaccination, noting it remains one of the safest and most effective ways to fight many severe infectious diseases. Issuing an executive order to reduce the number of childhood vaccines administered in the U.S. and split the measles, mumps, and rubella vaccination into three separate shots on Monday, Trump suggested a link between vaccin", "url": "https://seekingalpha.com/news/4631498-uk-regulator-reaffirms-safety-of-childhood-vaccination?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-12T13:13:40+00:00", "published_display": "12 Aug 2026 13:13", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 54, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.184, "duplicate_count": 1, "topics": ["Healthcare", "Regulation", "Split", "Vaccines"]}, {"title": "Why Revolution Medicines May Be Big Pharma\u2019s Next Takeover Target", "summary": "Quick Read RVMD has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. MRK ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure and CEO Robert Davis pledging to diversify its growth portfolio. It sounds nuts, but SoFi1 is giving new Active Invest users up to $3,000 in stock for a limited time, and all it takes is a $50 deposit to get started.2 See for yourself (Sponsor) Revolution Medicines (NASDAQ:RVMD) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform ", "url": "https://finance.yahoo.com/healthcare/articles/why-revolution-medicines-may-big-125024116.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T12:50:24+00:00", "published_display": "12 Aug 2026 12:50", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.37, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Fda Approval", "M A", "Oncology", "Price Target"]}, {"title": "Here Are Wednesday\u2019s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More", "summary": "Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price index will be released at the same time tomorrow. Economists forecast headline CPI to rise 0.1% month-over-month and 3.4% year-over-year, with core CPI expected to increase 0.2% month-over-month and 2.5% year-over-year. One thing is for sure; if the numbers come in hot and above expectations, the stock market could see a bout of heavy selling. All of the major ind", "url": "https://finance.yahoo.com/markets/stocks/articles/wednesday-top-wall-street-analyst-115341914.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:53:41+00:00", "published_display": "12 Aug 2026 11:53", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.367, "duplicate_count": 1, "topics": ["Crypto", "Earnings", "Price Target", "Price Target", "Upgrade Downgrade"]}, {"title": "Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children", "summary": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. The filings seek to broaden ENFLONSIA's indication in vulnerable pediatric groups where preventative options for RSV are limited. The dual U.S. and European regulatory milestones highlight Merck's efforts to build out its portfolio beyond oncology as attention on the future of Keytruda intensifies. For i", "url": "https://finance.yahoo.com/healthcare/articles/merck-mrk-wins-fda-ema-181430790.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T18:14:30+00:00", "published_display": "11 Aug 2026 18:14", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 55, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.284, "duplicate_count": 1, "topics": ["Fda Approval", "Healthcare", "Pharma", "Vaccines"]}, {"title": "MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?", "summary": "Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as higher sales of oncology drugs, including Keytruda, and contributions from new products like Winrevair, Welireg, and Capvaxive, and the Animal Health segment were partially offset by lower sales of Gardasil and some other vaccines. Sales of blockbuster PD-L1 inhibitor Keytruda increased 4% to $8.4 billion. Merck also raised its 2026 revenue", "url": "https://finance.yahoo.com/markets/stocks/articles/mrk-stock-5-6-month-134800162.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:48:00+00:00", "published_display": "11 Aug 2026 13:48", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.391, "duplicate_count": 1, "topics": ["Acquisitions", "Earnings", "Oncology", "Patent Expiration", "Pharmaceuticals", "Revenue Growth"]}, {"title": "The Galien Foundation Announces 2026 Prix Galien USA Nominees for \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\"", "summary": "A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the \"Best Biotechnology Product,\" \"Best Pharmaceutical Product,\" and \"Best Product for Rare/Orphan Diseases\" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo \"We are proud to recog", "url": "https://finance.yahoo.com/healthcare/articles/galien-foundation-announces-2026-prix-130000242.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T13:00:00+00:00", "published_display": "11 Aug 2026 13:00", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 69, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.447, "duplicate_count": 1, "topics": ["Biotech", "Fda Approval", "Pharmaceuticals", "Rare Diseases"]}, {"title": "ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer", "summary": "Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business Officer Appointments deepen vaccine development expertise and enhance global commercial and strategic leadership WESTON, Fla., August 11, 2026--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisit", "url": "https://finance.yahoo.com/healthcare/articles/iliad-biotechnologies-expands-board-directors-123000980.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:30:00+00:00", "published_display": "11 Aug 2026 12:30", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.252, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Vaccine Development"]}, {"title": "S&P 500 Companies' Quarterly Earnings Growth Eases Amid Healthcare Drop, Oppenheimer Says", "summary": "S&P 500 companies' quarterly earnings growth rate eased from a week ago amid a drop in the healthcar PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/markets/stocks/articles/p-500-companies-apos-quarterly-180206082.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T18:02:06+00:00", "published_display": "10 Aug 2026 18:02", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.339, "duplicate_count": 1, "topics": ["Growth Rate", "Quarterly Earnings"]}, {"title": "Glioma Market is Set for Tremendous Growth at a CAGR of 15% During the Study Period (2022\u20132036), as Novel Targeted Therapies and Immunotherapies are Gaining Momentum | DelveInsight", "summary": "DelveInsight Business Research LLP The glioma market is expected to witness steady growth over the coming years, driven by the rising incidence of primary brain tumors, increasing awareness, and advances in diagnostic technologies. The market is also benefiting from a robust pipeline of therapies, including Regorafenib (Bayer), AV-GBM-1 (Aivita Biomedical), Enzastaurin (DB-102) (Denovo Biopharma), Paxalisib (GDC-0084) (Kazia Therapeutics), and others, aimed at improving patient outcomes. New York, USA, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Glioma Market is Set for Tremendous Growth at a CAGR of 15", "url": "https://finance.yahoo.com/healthcare/articles/glioma-market-set-tremendous-growth-170000207.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T17:00:00+00:00", "published_display": "10 Aug 2026 17:00", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.387, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Glioma", "Market Research Reports", "Pharma"]}, {"title": "IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum", "summary": "Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while valuation and weak Zacks Style Scores temper the case for simply extrapolating the recent move. IMCR's 3-Month Rally Puts Growth in Focus IMCR shares have climbed more than 20% over the past 12 weeks. That compares with gains of 6.4% over four weeks and 0.6% over one week, making the longer recent advan", "url": "https://finance.yahoo.com/markets/stocks/articles/imcr-jumps-21-2-3-161600739.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T16:16:00+00:00", "published_display": "10 Aug 2026 16:16", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.335, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings", "Price Target"]}, {"title": "IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss", "summary": "Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consensus estimate of a loss of 1 cent. Kimmtrak remained the central growth driver, while a temporary U.S. distributor stocking benefit complicates the third-quarter setup. Higher research spending and a sizable cash balance also frame the company's push to broaden its melanoma opportunity. IMCR's Q2 Sales Beat Shows Kimmtrak Strength Kimmtrak generated $74.9 mill", "url": "https://finance.yahoo.com/healthcare/articles/imcr-q2-revenues-climb-18-153900256.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:39:00+00:00", "published_display": "10 Aug 2026 15:39", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.333, "duplicate_count": 1, "topics": ["Consensus Estimate", "Earnings", "Melanoma", "Pharma", "Ratings"]}, {"title": "BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?", "summary": "Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. BMY Outperforms Industry, Sector & S&P 500 IndexZacks Investment Research Image Source: Zacks Investment Research The company reported better-than-expected second-quarter results on July 30, supported by robust demand for Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag. Results were also boosted by strong Eliquis performan", "url": "https://finance.yahoo.com/healthcare/articles/bmy-rallies-16-2-three-151500081.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:15:00+00:00", "published_display": "10 Aug 2026 15:15", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.332, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Generic Competition", "Guidance", "Immuno Oncology"]}, {"title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "summary": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-09T13:05:04+00:00", "published_display": "09 Aug 2026 13:05", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 43, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.275, "duplicate_count": 1, "topics": ["Consensus Estimate", "Earnings", "Earnings Per Share", "Guidance", "Healthcare", "M A"]}, {"title": "Earnings Scorecard: 95% of healthcare firms deliver EPS wins this week", "summary": "Major healthcare heavyweights, including Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]), reported their quarterly earnings this week, pushing the healthcare sector into positive territory after five consecutive sessions of losses. The State Street Health Care Select Sector SPDR ETF [https://seekingalpha.com/symbol/XLV] (XLV [https://seekingalpha.com/symbol/XLV]) rose 1.36% in the week so far. On a YTD basis, XLV has added more than 5%; however, it is lagging behind the broader S&P ", "url": "https://seekingalpha.com/news/4629325-earnings-scorecard-95-healthcare-firm-deliver-eps-wins-this-week?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-08T15:15:33+00:00", "published_display": "08 Aug 2026 15:15", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 57, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.235, "duplicate_count": 1, "topics": ["Biotech", "Earnings", "Earnings News", "Guidance", "Healthcare", "Pharma"]}], "industry": [], "sector": []}, "total_fetched": 17, "total_unique": 17, "total_relevant": 17, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 17}, "raw_articles": 17, "unique_stories": 17, "duplicates_removed": 0, "relevant_stories": 17, "current_evidence": 17, "direct_evidence": 17, "eodhd_articles": 17, "eodhd": {"configured": true, "status": "healthy", "calls_used": 290, "call_budget": 500, "budget_used_pct": 58.0, "requests_made": 58, "last_success_at": "2026-08-13T10:15:22.511002+00:00", "newest_seen_at": "2026-08-13T10:01:45+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3282, "unmapped_mentions": 1903}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-09T16:08:04.843353+00:00", "durable_newest_article_at": "2026-08-09T13:05:04+00:00", "durable_story_count": 1}, "sentiment_summary": {"positive": 13, "negative": 2, "neutral": 2, "score": 66, "raw_score": 70, "total": 17, "evidence_count": 17, "effective_articles": 16.09, "direct_story_count": 17, "industry_story_count": 0, "sector_story_count": 0, "story_count": 17, "source_count": 2, "source_concentration": 0.7924, "direct_share": 100, "dispersion": 15, "confidence": 83, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-12T23:41:00+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 79, "events": [{"event": "earnings", "label": "Earnings", "weight": 5.4, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 1.8, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.8, "count": 3}, {"event": "general", "label": "Market update", "weight": 1.2, "count": 2}], "positive_events": 13, "negative_events": 2, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 17}, "raw_articles": 17, "unique_stories": 17, "duplicates_removed": 0, "relevant_stories": 17, "current_evidence": 17, "direct_evidence": 17, "eodhd_articles": 17, "eodhd": {"configured": true, "status": "healthy", "calls_used": 290, "call_budget": 500, "budget_used_pct": 58.0, "requests_made": 58, "last_success_at": "2026-08-13T10:15:22.511002+00:00", "newest_seen_at": "2026-08-13T10:01:45+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3282, "unmapped_mentions": 1903}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-09T16:08:04.843353+00:00", "durable_newest_article_at": "2026-08-09T13:05:04+00:00", "durable_story_count": 1}}, "market_context": {"has_market_context": true, "latest_close": 128.58, "latest_week": "2026-08-07", "one_week_move": -1.2, "four_week_move": 4.1, "twelve_week_move": 16.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.563089, "market_dynamics_buy_signal": false, "relative_strength": 8.146152, "fair_value_gap": 26.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.5854, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.2% over one week, +4.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 78, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 14}, {"label": "seekingalpha.com", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 17}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 9}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 3}, {"label": "Market update", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "66/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "83/100", "tone": "positive", "text": "16.09 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "17", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "15/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.2% over one week, +4.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "5 Insightful Analyst Questions From Merck\u2019s Q2 Earnings Call"}], "updated_at": "2026-08-09T16:08:04.843353+00:00", "detail_intelligence": {"headline": "Positive news being faded", "summary": "Constructive news tone is drawn from 17 fresh independent stories, including 17 company-specific items across 2 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 66, "display": "66", "tone": "positive", "note": "Constructive news tone"}, {"label": "Evidence confidence", "value": 83, "display": "83", "tone": "positive", "note": "high confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "17 direct stories"}, {"label": "Evidence agreement", "value": 85, "display": "85", "tone": "positive", "note": "15/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 100, "note": "16.09 effective stories"}, {"label": "Source breadth", "value": 40, "note": "2 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 74, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 85, "note": "cross-story consistency"}, {"label": "Source independence", "value": 21, "note": "lower publisher concentration"}], "freshness": 74, "source_independence": 21, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 683.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 1, "score": 57, "tone": "neutral", "x": 729.0, "y": 122.3, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-08-09", "label": "09 Aug", "count": 1, "score": 43, "tone": "neutral", "x": 774.8, "y": 147.7, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-08-10", "label": "10 Aug", "count": 5, "score": 70, "tone": "positive", "x": 820.6, "y": 98.6, "volume_height": 43.3, "volume_y": 222.7}, {"date": "2026-08-11", "label": "11 Aug", "count": 4, "score": 71, "tone": "positive", "x": 866.4, "y": 96.8, "volume_height": 34.7, "volume_y": 231.3}, {"date": "2026-08-12", "label": "12 Aug", "count": 6, "score": 74, "tone": "positive", "x": 912.2, "y": 91.3, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "729.0,122.3 774.8,147.7 820.6,98.6 866.4,96.8 912.2,91.3", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Improving", "tone": "positive", "recent_score": 72, "prior_score": 49, "delta": 23, "recent_count": 15, "prior_count": 2, "volume_delta": 13}, "freshness_buckets": [{"label": "Last 24 hours", "count": 6, "share": 35}, {"label": "1 to 3 days", "count": 9, "share": 53}, {"label": "4 to 7 days", "count": 2, "share": 12}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 14, "share": 82, "score": 73, "tone": "positive"}, {"label": "seekingalpha.com", "count": 3, "share": 18, "score": 51, "tone": "neutral"}], "event_profile": [{"label": "Earnings", "count": 9, "share": 53, "score": 72, "tone": "positive"}, {"label": "Analyst action", "count": 3, "share": 18, "score": 68, "tone": "positive"}, {"label": "Regulatory and legal", "count": 3, "share": 18, "score": 67, "tone": "positive"}, {"label": "Market update", "count": 2, "share": 12, "score": 67, "tone": "positive"}], "topics": [{"label": "Earnings", "count": 8, "share": 47}, {"label": "Biotech", "count": 7, "share": 41}, {"label": "Pharma", "count": 6, "share": 35}, {"label": "Price Target", "count": 4, "share": 24}, {"label": "Oncology", "count": 4, "share": 24}, {"label": "Healthcare", "count": 4, "share": 24}, {"label": "Guidance", "count": 4, "share": 24}, {"label": "Fda Approval", "count": 4, "share": 24}, {"label": "Clinical Trials", "count": 4, "share": 24}, {"label": "Vaccines", "count": 2, "share": 12}], "supporting": [{"label": "Direct evidence", "text": "17 current stories are mapped specifically to MRK."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 85/100, indicating a comparatively coherent tape."}], "tempering": [{"label": "Source breadth", "text": "Only 2 publishers currently contribute to the measured read."}, {"label": "Price disagreement", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "5 Insightful Analyst Questions From Merck\u2019s Q2 Earnings Call", "summary": "5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, \"Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline.\" While market reaction was muted, management acknowledg", "url": "https://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-merck-234100386.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T23:41:00+00:00", "published_display": "12 Aug 2026 23:41", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.505, "duplicate_count": 1, "topics": ["Clinical Trials", "Earnings", "Guidance", "Oncology", "Pharma"]}, "article_count": 17, "updated_at": "2026-08-09T16:08:04.843353+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 138.5, "label": "13 Feb 2026", "close": 119.64, "index": 100.0}, {"x": 78.1, "y": 132.5, "label": "20 Feb 2026", "close": 120.48, "index": 100.7}, {"x": 114.2, "y": 121.3, "label": "27 Feb 2026", "close": 122.01, "index": 102.0}, {"x": 150.3, "y": 178.6, "label": "06 Mar 2026", "close": 114.1, "index": 95.4}, {"x": 186.4, "y": 179.9, "label": "13 Mar 2026", "close": 113.92, "index": 95.2}, {"x": 222.4, "y": 184.1, "label": "20 Mar 2026", "close": 113.34, "index": 94.7}, {"x": 258.5, "y": 144.9, "label": "27 Mar 2026", "close": 118.75, "index": 99.3}, {"x": 294.6, "y": 136.0, "label": "03 Apr 2026", "close": 119.98, "index": 100.3}, {"x": 330.7, "y": 132.1, "label": "10 Apr 2026", "close": 120.53, "index": 100.7}, {"x": 366.8, "y": 149.0, "label": "17 Apr 2026", "close": 118.2, "index": 98.8}, {"x": 402.9, "y": 200.5, "label": "24 Apr 2026", "close": 111.08, "index": 92.8}, {"x": 439.0, "y": 198.6, "label": "01 May 2026", "close": 111.34, "index": 93.1}, {"x": 475.1, "y": 204.2, "label": "08 May 2026", "close": 110.56, "index": 92.4}, {"x": 511.2, "y": 204.2, "label": "15 May 2026", "close": 110.56, "index": 92.4}, {"x": 547.2, "y": 125.0, "label": "22 May 2026", "close": 121.51, "index": 101.6}, {"x": 583.3, "y": 151.5, "label": "29 May 2026", "close": 117.85, "index": 98.5}, {"x": 619.4, "y": 136.6, "label": "05 Jun 2026", "close": 119.9, "index": 100.2}, {"x": 655.5, "y": 149.1, "label": "12 Jun 2026", "close": 118.18, "index": 98.8}, {"x": 691.6, "y": 180.3, "label": "19 Jun 2026", "close": 113.87, "index": 95.2}, {"x": 727.7, "y": 73.2, "label": "26 Jun 2026", "close": 128.66, "index": 107.5}, {"x": 763.8, "y": 66.7, "label": "03 Jul 2026", "close": 129.56, "index": 108.3}, {"x": 799.9, "y": 110.3, "label": "10 Jul 2026", "close": 123.54, "index": 103.3}, {"x": 836.0, "y": 81.6, "label": "17 Jul 2026", "close": 127.5, "index": 106.6}, {"x": 872.0, "y": 55.8, "label": "24 Jul 2026", "close": 131.07, "index": 109.6}, {"x": 908.1, "y": 62.1, "label": "31 Jul 2026", "close": 130.2, "index": 108.8}, {"x": 944.2, "y": 73.8, "label": "07 Aug 2026", "close": 128.58, "index": 107.5}], "sentiment_points": [{"x": 725.5, "y": 117.1, "label": "25 Jun 2026", "score": 57}, {"x": 725.7, "y": 119.0, "label": "25 Jun 2026", "score": 56}, {"x": 730.3, "y": 119.0, "label": "26 Jun 2026", "score": 56}, {"x": 732.3, "y": 120.8, "label": "26 Jun 2026", "score": 55}, {"x": 734.3, "y": 119.0, "label": "27 Jun 2026", "score": 56}, {"x": 748.9, "y": 117.1, "label": "30 Jun 2026", "score": 57}, {"x": 753.1, "y": 120.8, "label": "30 Jun 2026", "score": 55}, {"x": 754.3, "y": 122.6, "label": "01 Jul 2026", "score": 54}, {"x": 759.1, "y": 124.5, "label": "02 Jul 2026", "score": 53}, {"x": 764.2, "y": 122.6, "label": "03 Jul 2026", "score": 54}, {"x": 766.2, "y": 124.5, "label": "03 Jul 2026", "score": 53}, {"x": 766.8, "y": 124.5, "label": "03 Jul 2026", "score": 53}, {"x": 768.1, "y": 119.0, "label": "03 Jul 2026", "score": 56}, {"x": 769.6, "y": 120.8, "label": "04 Jul 2026", "score": 55}, {"x": 770.5, "y": 120.8, "label": "04 Jul 2026", "score": 55}, {"x": 770.8, "y": 119.0, "label": "04 Jul 2026", "score": 56}, {"x": 771.4, "y": 119.0, "label": "04 Jul 2026", "score": 56}, {"x": 773.2, "y": 120.8, "label": "04 Jul 2026", "score": 55}, {"x": 774.6, "y": 120.8, "label": "05 Jul 2026", "score": 55}, {"x": 782.5, "y": 117.1, "label": "06 Jul 2026", "score": 57}, {"x": 783.7, "y": 119.0, "label": "06 Jul 2026", "score": 56}, {"x": 795.3, "y": 119.0, "label": "09 Jul 2026", "score": 56}, {"x": 797.1, "y": 120.8, "label": "09 Jul 2026", "score": 55}, {"x": 800.3, "y": 119.0, "label": "10 Jul 2026", "score": 56}, {"x": 800.4, "y": 119.0, "label": "10 Jul 2026", "score": 56}, {"x": 803.7, "y": 117.1, "label": "10 Jul 2026", "score": 57}, {"x": 808.9, "y": 122.6, "label": "11 Jul 2026", "score": 54}, {"x": 816.9, "y": 122.6, "label": "13 Jul 2026", "score": 54}, {"x": 821.0, "y": 120.8, "label": "14 Jul 2026", "score": 55}, {"x": 823.9, "y": 122.6, "label": "14 Jul 2026", "score": 54}, {"x": 826.6, "y": 122.6, "label": "15 Jul 2026", "score": 54}, {"x": 827.5, "y": 122.6, "label": "15 Jul 2026", "score": 54}, {"x": 838.7, "y": 113.4, "label": "17 Jul 2026", "score": 59}, {"x": 851.8, "y": 109.8, "label": "20 Jul 2026", "score": 61}, {"x": 853.7, "y": 111.6, "label": "20 Jul 2026", "score": 60}, {"x": 862.2, "y": 115.3, "label": "22 Jul 2026", "score": 58}, {"x": 869.2, "y": 117.1, "label": "23 Jul 2026", "score": 57}, {"x": 869.8, "y": 117.1, "label": "23 Jul 2026", "score": 57}, {"x": 876.3, "y": 117.1, "label": "24 Jul 2026", "score": 57}, {"x": 891.0, "y": 120.8, "label": "27 Jul 2026", "score": 55}, {"x": 892.0, "y": 119.0, "label": "27 Jul 2026", "score": 56}, {"x": 893.7, "y": 122.6, "label": "28 Jul 2026", "score": 54}, {"x": 895.3, "y": 122.6, "label": "28 Jul 2026", "score": 54}, {"x": 903.7, "y": 120.8, "label": "30 Jul 2026", "score": 55}, {"x": 906.9, "y": 119.0, "label": "30 Jul 2026", "score": 56}, {"x": 908.5, "y": 119.0, "label": "31 Jul 2026", "score": 56}, {"x": 908.9, "y": 119.0, "label": "31 Jul 2026", "score": 56}, {"x": 910.5, "y": 119.0, "label": "31 Jul 2026", "score": 56}, {"x": 928.1, "y": 120.8, "label": "03 Aug 2026", "score": 55}, {"x": 939.5, "y": 120.8, "label": "06 Aug 2026", "score": 55}, {"x": 957.2, "y": 119.0, "label": "09 Aug 2026", "score": 56}, {"x": 958.0, "y": 119.0, "label": "09 Aug 2026", "score": 56}], "price_path": "42.0,138.5 78.1,132.5 114.2,121.3 150.3,178.6 186.4,179.9 222.4,184.1 258.5,144.9 294.6,136.0 330.7,132.1 366.8,149.0 402.9,200.5 439.0,198.6 475.1,204.2 511.2,204.2 547.2,125.0 583.3,151.5 619.4,136.6 655.5,149.1 691.6,180.3 727.7,73.2 763.8,66.7 799.9,110.3 836.0,81.6 872.0,55.8 908.1,62.1 944.2,73.8", "sentiment_path": "725.5,117.1 725.7,119.0 730.3,119.0 732.3,120.8 734.3,119.0 748.9,117.1 753.1,120.8 754.3,122.6 759.1,124.5 764.2,122.6 766.2,124.5 766.8,124.5 768.1,119.0 769.6,120.8 770.5,120.8 770.8,119.0 771.4,119.0 773.2,120.8 774.6,120.8 782.5,117.1 783.7,119.0 795.3,119.0 797.1,120.8 800.3,119.0 800.4,119.0 803.7,117.1 808.9,122.6 816.9,122.6 821.0,120.8 823.9,122.6 826.6,122.6 827.5,122.6 838.7,113.4 851.8,109.8 853.7,111.6 862.2,115.3 869.2,117.1 869.8,117.1 876.3,117.1 891.0,120.8 892.0,119.0 893.7,122.6 895.3,122.6 903.7,120.8 906.9,119.0 908.5,119.0 908.9,119.0 910.5,119.0 928.1,120.8 939.5,120.8 957.2,119.0 958.0,119.0", "price_change": 7.5, "sentiment_change": -1, "latest_close": 128.58, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}